title: Effects of cytokines on the pituitary-adrenal axis in cancer patients.
abstract: Cytokines, which include interferons (IFNs), interleukins (ILs), and tumor necrosis factor (TNF), are immunoregulatory proteins produced by lymphocytes and inflammatory cells. Several cytokines, most noteworthy IFNs and ILs, stimulate glucocorticoid secretion. In this study, the effects of variable doses and repetitive administration of IFNs and TNF on secretion of pituitary hormones and cortisol were measured. Patients were given for a period of 15 days on alternating days injections of IFN-beta (IFN-beta ser), 90 or 450 x 10(6) IU, IFN-gamma, 0.1-100 x 10(6) IU, or TNF 125-275 micrograms/m2. Sixty to 120 min after IFN-beta ser injection median levels of cortisol, adrenocorticotropin (ACTH), prolactin (PRL), and growth hormone (GH) rose two-fold. Urinary free cortisol excretion increased significantly during the day following IFN-beta ser administration. IFN-gamma > or = 30 x 10(6) IU caused a comparable rise in plasma cortisol. TNF induced two- to four-fold increases in ACTH and cortisol. The fact that increased cortisol secretion was associated with a rise in the level of ACTH as well as PRL and GH suggests that the cytokines increased cortisol by stimulating the anterior pituitary. The hormonal response induced by cytokines was unrelated to their pyrogenic effect, undiminished with repetitive treatment, and not dose-dependent above a threshold level. These observations reinforce the concept of a physiologic link between the immune system and the hypothalamic-pituitary-adrenal (HPA) axis.
authors.affiliation: Department of Medicine, University of Wisconsin, Madison.
authors.forename: W E
authors.initials: WE
authors.lastname: Nolten
authors.forename: D
authors.initials: D
authors.lastname: Goldstein
authors.forename: M
authors.initials: M
authors.lastname: Lindstrom
authors.forename: M V
authors.initials: MV
authors.lastname: McKenna
authors.forename: I H
authors.initials: IH
authors.lastname: Carlson
authors.forename: D L
authors.initials: DL
authors.lastname: Trump
authors.forename: J
authors.initials: J
authors.lastname: Schiller
authors.forename: E C
authors.initials: EC
authors.lastname: Borden
authors.forename: E N
authors.initials: EN
authors.lastname: Ehrlich
mesh_terms: D000324:Adrenocorticotropic Hormone / Q000378:metabolism; D000328:Adult; D000368:Aged; D016207:Cytokines / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism*; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000008:administration & dosage; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D010907:Pituitary Hormones / Q000378:metabolism*; D010913:Pituitary-Adrenal System / Q000187:drug effects*; D011388:Prolactin / Q000378:metabolism
chemical_list: D016207:Cytokines; D010907:Pituitary Hormones; D000068576:Interferon beta-1b; D016899:Interferon-beta; D000324:Adrenocorticotropic Hormone; D011388:Prolactin; D013006:Growth Hormone; D006854:Hydrocortisone; D000068556:Interferon beta-1a